
Title:
Amoxicillin/clavulanic acid
Text:
Combination antibiotic drug


.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}Amoxicillin/clavulanic acidCombination ofAmoxicillinPenicillin antibioticClavulanic acidBeta-lactamase inhibitorClinical dataTrade namesAugmentin, Clavulin, Amoclan, others[1]AHFS/Drugs.comMonographMedlinePlusa685024License data
US DailyMed: Amoxicillin_and_clavulanate
US FDA: Augmentin
Pregnancycategory
AU: B1

Routes ofadministrationBy mouth, intravenous[2]ATC codeJ01CR02 (WHO) Legal statusLegal status
AU: S4 (Prescription only) 
CA:  ℞-only 
UK: POM (Prescription only) 
US: ℞-only 
IdentifiersCAS Number26787-78-0 N58001-44-8PubChem CID643592323665637ChemSpider4940608 YUNII9EM05410Q923521W1S24KEGGD06485ChEMBLChEMBL1697738 YCompTox Dashboard (EPA)DTXSID40225477 Chemical and physical dataFormulaC24H27KN4O10SMolar mass602.66 g·mol−13D model (JSmol)Interactive image
SMILES
CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)C(=O)O)C.C1C2N(C1=O)C(C(=CCO)O2)C(=O)[O-].[K+]

InChI
InChI=DWHGNUUWCJZQHO-ZVDZYBSKSA-MKey:1S/C16H19N3O5S.C8H9NO5.K/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7;10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4;/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24);1,6-7,10H,2-3H2,(H,12,13);/q;;+1/p-1/b;4-1-;/t9-,10-,11+,14-;6-,7-;/m11./s1
.mw-parser-output .nobold{font-weight:normal} NY (what is this?)  (verify)
Amoxicillin/clavulanic acid, also known as co-amoxiclav or amox-clav, is an antibiotic medication used for the treatment of a number of bacterial infections.[3] It is a combination consisting of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor.[3] It is specifically used for otitis media, streptococcal pharyngitis, pneumonia, cellulitis, urinary tract infections, and animal bites.[3] It is taken by mouth or by injection into a vein.[2]
Common side effects include diarrhea, vomiting, and allergic reactions.[3] It also increases the risk of yeast infections, headaches, and blood clotting problems.[2][4] It is not recommended in people with a history of a penicillin allergy.[2] It is relatively safe for use during pregnancy.[3]
Amoxicillin/clavulanic acid was approved for medical use in the United States in 1984.[3] It is on the World Health Organization's List of Essential Medicines.[5] The World Health Organization classifies amoxicillin/clavulanic-acid as critically important for human medicine.[6] It is available as a generic medication.[3]  In 2019, it was the 93rd most commonly prescribed medication in the United States, with more than 8 million prescriptions.[7][8]

Contents

1 Medical uses
2 Adverse effects
3 History
4 Preparations
5 Veterinary use

5.1 Bacterial resistance


6 References
7 External links



Medical uses[edit]
Amoxicillin/clavulanic acid is widely used to treat or prevent many infections caused by susceptible bacteria, such as:

urinary tract infections
respiratory tract infections
skin and soft tissue infections
sinus infections
tonsillitis
cat scratches
infections caused by the bacterial flora of the mouth, such as:
dental infections
infected animal bites
infected human bites (including uncomplicated "clenched-fist" or "reverse-bite" injuries)[9][10]
It is also used for tuberculosis that is resistant to other treatments.[3]World health organisation recommends giving amoxicillin-clavulanate along with meropenem as one of the therapeutic options in drug resistant tuberculosis, where clavulanate and not amoxicillin is being relied upon for anti TB activity. However, across the spectrum of dosage of amoxicillin-clavulanate combination, the dose of clavulanate is constant at 125 mg, whereas the dose of amoxicillin varies at 250 mg, 500 mg and 875 mg. Thus the use of low dose amoxicillin-clavulanate in combination with meropenem may be used in part of treatment regime for drug resistant TB and this has been demonstrated in a clinical setting also.[11]
This combination results in an antibiotic with an increased spectrum of action and restored efficacy against amoxicillin-resistant bacteria that produce β-lactamase.[citation needed]

Adverse effects[edit]
Possible side effects include diarrhea, vomiting, nausea, thrush, and skin rash. These do not usually require medical attention. As with all antimicrobial agents, antibiotic-associated diarrhea due to Clostridium difficile infection—sometimes leading to pseudomembranous colitis—may occur during or after treatment with amoxicillin/clavulanic acid.[10]
Rarely, cholestatic jaundice (also referred to as cholestatic hepatitis, a form of liver toxicity) has been associated with amoxicillin/clavulanic acid. The reaction may occur up to several weeks after treatment has stopped, and usually takes weeks to resolve. It is more frequent in men, older people, and those who have taken long courses of treatment; the estimated overall incidence is one in 100,000 exposures.[10] In the United Kingdom, co-amoxiclav carries a warning from the Committee on Safety of Medicines to this effect.[9]
As all aminopenicillins, amoxicillin has been associated with Stevens–Johnson syndrome/toxic epidermal necrolysis, although these reactions are very rare.[10][12]

History[edit]
British scientists working at Beecham (now part of GlaxoSmithKline), filed for US patent protection for the drug combination in 1979. 
They marketed it under the trade name Augmentin.[9] A patent was granted in 1985.[13][14]

Preparations[edit]
Amoxicillin/clavulanic acid is the International Nonproprietary Name (INN) and co-amoxiclav is the British Approved Name (BAN).[citation needed]
Many branded products indicate their strengths as the quantity of amoxicillin. Augmentin 250, for example, contains 250 mg of amoxicillin and 125 mg of clavulanic acid.[9][15]
An intravenous preparation has been available in the UK since 1985,[16] but no parenteral preparation is available in the US;[citation needed] the nearest equivalent is ampicillin/sulbactam.[citation needed]
Suspensions of amoxicillin/clavulanic acid are available for use in children.[citation needed] They must be refrigerated to maintain effectiveness.[citation needed]

Veterinary use[edit]
Amoxicillin/clavulanic acid is used in numerous animals for a variety of conditions:

Dogs: periodontitis, kennel cough[17][18]
Cats: urinary tract infections, skin and soft tissue infections[citation needed]
Calves: enteritis, navel ill[citation needed]
Cattle: respiratory tract infections, soft tissue infections, metritis, mastitis[citation needed]
Pigs: respiratory tract infections, colibacillosis, mastitis, metritis, agalactia[citation needed]
In combination with prednisolone, it is used for intramammary infusion for the treatment of mastitis in lactating cows.[citation needed] Trade names include Clavaseptin, Clavamox, and Synulox.[citation needed]
Amoxicillin/clavulanic acid is banned from use in domestic-food animals (cattle, swine, etc.) in both the US and Europe;[citation needed] in the UK, Synulox can be used in domestic-food animals as long as a specified withdrawal period is observed.[citation needed]

Bacterial resistance[edit]
Bacterial antibiotic resistance is a growing problem in veterinary medicine. Amoxicillin/clavulanic acid is reported to be effective against clinical Klebsiella infections, but is not efficacious against Pseudomonas infections.[19]

References[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 97. ISBN 9781284057560.

^ Jump up to: a b c d World Health Organization (2009).  Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 102. hdl:10665/44053. ISBN 9789241547659.

^ Jump up to: a b c d e f g h "Amoxicillin and Clavulanate Potassium". The American Society of Health-System Pharmacists. Archived from the original on 29 November 2016. Retrieved 8 December 2016.

^ Gillies, M; Ranakusuma, A; Hoffmann, T; Thorning, S; McGuire, T; Glasziou, P; Del Mar, C (17 November 2014). "Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication". Canadian Medical Association Journal. 187 (1): E21-31. doi:10.1503/cmaj.140848. PMC 4284189. PMID 25404399.

^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

^ World Health Organization (2019). Critically important antimicrobials for human medicine (6th revision ed.). Geneva: World Health Organization. hdl:10665/312266. ISBN 9789241515528.

^ "The Top 300 of 2019". ClinCalc. Retrieved 16 October 2021.

^ "Amoxicillin; Clavulanate - Drug Usage Statistics". ClinCalc. Retrieved 16 October 2021.

^ Jump up to: a b c d British National Formulary (57 ed.). March 2009.

^ Jump up to: a b c d Gordon D (2010). "Amoxicillin–Clavulanic Acid (Co-Amoxiclav)".  In Grayson ML;  et al. (eds.). Kucers' the Use of Antibiotics: a Clinical Review of Antibacterial, Antifungal, Antiparasitic and Antiviral Drugs. London: Hodder Arnold/ASM Press. pp. 193–4. ISBN 978-0-340-92767-0.

^ Mishra, Gyanshankar; Caminero, Jose (2018). "First Successful Use of Low Dose Amoxicillin-Clavulanic Acid in Management of Drug Resistant Tuberculosis". Journal of Clinical and Diagnostic Research. 12 (10): OD08–OD10. doi:10.7860/JCDR/2018/37279.12145. Retrieved 7 May 2021.

^ Harr T, French LE (2010). "Toxic epidermal necrolysis and Stevens-Johnson syndrome". Orphanet Journal of Rare Diseases. 5: 39. doi:10.1186/1750-1172-5-39. PMC 3018455. PMID 21162721.

^ .mw-parser-output .citation{word-wrap:break-word}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}US 4441609 

^ Bryan, Jenny (23 June 2011). "Still going strong at 30: co-amoxiclav". The Pharmaceutical Journal. 286: 762.

^ "Augmentin -- Prescribing Information" (PDF). December 2006. Archived (PDF) from the original on 20 December 2013.

^ Davies BE, Boon R, Horton R, Reubi FC, Descoeudres CE (October 1988). "Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of Augmentin". British Journal of Clinical Pharmacology. 26 (4): 385–90. doi:10.1111/j.1365-2125.1988.tb03395.x. PMC 1386558. PMID 3190988.

^ "Canine Infectious Tracheobronchitis (Kennel Cough)". Archived from the original on 21 May 2006. Retrieved 30 May 2013.

^ "Kennel Cough - Symptoms and Treatment". Archived from the original on 10 May 2013. Retrieved 30 May 2013.

^ Federation of Veterinarians in Europe Position Paper: "Antibiotic Resistance & Prudent Use of Antibiotics in Veterinary Medicine"


External links[edit]
"Amoxicillin / clavulanic acid". Drug Information Portal. U.S. National Library of Medicine.
.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteGlaxoSmithKlineSubsidiaries
GlaxoSmithKline Pakistan
GlaxoSmithKline Pharmaceuticals Ltd
Stiefel Laboratories
Tesaro
ViiV Healthcare (85%)
Predecessors,acquisitions
Allen & Hanburys
Beecham Group
Block Drug
Burroughs Wellcome
Glaxo
Glaxo Wellcome
Human Genome Sciences
Recherche et Industrie Thérapeutiques
Reliant Pharmaceuticals
S. E. Massengill Company
SmithKline Beecham
Smith, Kline & French
ProductsCurrentPharma
Advair
Alli
Augmentin
Avandia
Beconase
Boniva
Flixonase
Hycamtin
Lamictal
Paxil/Seroxat
Serlipet
Tagamet
Ventolin
Wellbutrin/Zyban
Zantac … more
Vaccines
Hepatyrix
Pandemrix
Shingrix
Twinrix
Other
Aquafresh
Centrum
Horlicks
Nicoderm
Nicorette
NiQuitin
Sensodyne
Tums … more
Former
BC Powder
Geritol
Goody's Powder
Lucozade
Ribena
PeopleBoard of Directors
Philip Hampton
Emma Walmsley
Simon Dingemans
Roy M. Anderson
Manvinder Banga 
Patrick Vallance
Vivienne Cox
Lynn Elsenhans
Jesse Goodman
Judy Lewent
Urs Rohner
Laurie Glimcher
Other
Thomas Beecham
Silas M. Burroughs
Mahlon Kline
John K. Smith
Henry Wellcome
Andrew Witty
Chris Gent
Litigation
Canada v. GlaxoSmithKline Inc.
Christopher v. SmithKline Beecham Corp.
GlaxoSmithKline Services Unlimited v Commission
United States v. Glaxo Group Ltd.
United States v. GlaxoSmithKline
Other
Drug Industry Documents Archive
GlaxoSmithKline Prize
Side Effects
Study 329

 Category

vteAntibacterials active on the cell wall and envelope (J01C-J01D)Beta-lactams(inhibit synthesisof peptidoglycanlayer of bacterialcell wall by bindingto and inhibitingPBPs, a group ofD-alanyl-D-alaninetranspeptidases)Penicillins (Penams)Narrowspectrumβ-lactamase sensitive(1st generation)
Benzylpenicillin (G)#
Benzathine benzylpenicillin#
Procaine benzylpenicillin#
Phenoxymethylpenicillin (V)#
Propicillin‡
Pheneticillin‡
Azidocillin‡
Clometocillin‡
Penamecillin‡
β-lactamase resistant(2nd generation)
Cloxacillin# (Dicloxacillin
Flucloxacillin)
Oxacillin
Nafcillin
Methicillin‡
ExtendedspectrumAminopenicillins (3rd generation)
Amoxicillin#
Ampicillin# (Pivampicillin
Hetacillin‡
Bacampicillin‡
Metampicillin‡
Talampicillin‡)
Epicillin‡
Carboxypenicillins (4th generation)
Ticarcillin
Carbenicillin‡ / Carindacillin‡
Temocillin‡
Ureidopenicillins (4th generation)
Piperacillin
Azlocillin‡
Mezlocillin‡
Other
Mecillinam (Pivmecillinam)
Sulbenicillin‡
Carbapenems / Penems
Carbapenems (Ertapenem
Antipseudomonal (Doripenem
Imipenem
Meropenem)
Biapenem‡
Panipenem)
Penems (Faropenem
Ritipenem§)
CephemsCephalosporinsCephamycinsCarbacephems1st generation
Cefazolin#
Cefalexin #
Cefadroxil
Cefapirin
Cefazedone‡
Cefazaflur‡
Cefradine‡
Cefroxadine‡
Ceftezole‡
Cefaloglycin‡
Cefacetrile‡
Cefalonium‡
Cefaloridine‡
Cefalotin
Cefatrizine‡
2nd generation
Cefaclor
Cefprozil
Cefuroxime
Cefuroxime axetil
Cefamandole‡
Cefonicid‡
Ceforanide‡
Cefuzonam‡
Cephamycin (Cefoxitin
Cefotetan
Cefminox‡
Cefbuperazone‡
Cefmetazole‡)
Carbacephem (Loracarbef‡)
3rd generation
Cefixime#
Ceftriaxone#
Cefotaxime#
Antipseudomonal (Ceftazidime#
Cefoperazone‡)
Cefdinir
Cefcapene
Cefdaloxime
Ceftizoxime
Cefmenoxime
Cefpiramide
Cefpodoxime
Ceftibuten
Cefditoren
Cefotiam‡
Cefetamet‡
Cefodizime‡
Cefpimizole‡
Cefsulodin‡
Cefteram‡
Ceftiolene‡
Oxacephem (Flomoxef‡
Latamoxef‡)
4th generation
Cefepime
Cefozopran‡
Cefpirome
Cefquinome‡
5th generation
Ceftaroline fosamil
Ceftolozane
Ceftobiprole
Siderophore
Cefiderocol#
Veterinary
Ceftiofur
Cefquinome
Cefovecin
Monobactams
Aztreonam
Tigemonam‡
Carumonam‡
Nocardicin A‡
β-lactamase inhibitors
Penam (Sulbactam
Tazobactam)
Clavam (Clavulanic acid)
non-β-lactam (Relebactam
Avibactam
Vaborbactam)
Combinations
Amoxicillin/clavulanic acid#
Ampicillin/flucloxacillin
Ampicillin/sulbactam (Sultamicillin)
Benzathine benzylpenicillin/procaine benzylpenicillin
Cefoperazone/sulbactam
Ceftazidime/avibactam
Ceftolozane/tazobactam
Imipenem/cilastatin#
Imipenem/cilastatin/relebactam
Meropenem/vaborbactam
Panipenem/betamipron
Piperacillin/tazobactam
Ticarcillin/clavulanic acid
PolypeptidesGlycopeptides
Inhibit PG chain elongation: Vancomycin# (Oritavancin
Telavancin)
Teicoplanin (Dalbavancin)
Ramoplanin§
Ristocetin‡
Avoparcin
Lipopeptides
Insert into bacterial cell wall causing perforation and depolarization: Daptomycin
Surfactin
Polymyxins
Bind to LPS in the outer bacterial membrane, acting in detergent-like fashion: Colistin
Polymyxin B
Intracellular
Inhibit PG subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
DADAL/AR inhibitors (Cycloserine)
bactoprenol inhibitors (Bacitracin)
Other
Hydrolyze NAM-NAG
lysozyme
Tyrothricin
Gramicidin
Tyrocidine
Isoniazid#
Teixobactin

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;justify-content:center;align-items:baseline}.mw-parser-output .portal-bar-bordered{padding:0 2em;background-color:#fdfdfd;border:1px solid #a2a9b1;clear:both;margin:1em auto 0}.mw-parser-output .portal-bar-unbordered{padding:0 1.7em;margin-left:0}.mw-parser-output .portal-bar-header{margin:0 1em 0 0.5em;padding:0.2em 0;flex:0 0 auto;min-height:24px;line-height:22px}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0 1 auto;padding:0.15em 0;column-gap:1em}.mw-parser-output .portal-bar-item{display:flex;align-items:baseline;margin:0.15em 0;min-height:24px;text-align:left}.mw-parser-output .portal-bar-logo{width:22px;line-height:22px;margin:0 0.2em;text-align:right}.mw-parser-output .portal-bar-link{margin:0 0.2em;text-align:left}@media screen and (max-width:768px){.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;flex-flow:column wrap}.mw-parser-output .portal-bar-header{text-align:center;flex:0;padding-left:0.5em;margin:0 auto}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0;margin:0 auto;column-gap:1em;border-top:1px solid #a2a9b1}}.mw-parser-output .navbox+link+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .navbox+style+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .portal-bar+.navbox-styles+.navbox{margin-top:-1px}Portal:Medicine





